Search
Plicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnPlicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.
Categories: Compounds used in a research, industrial, or household settingAlvespimycin
go.drugbank.com/drugs/DB12442InvestigationalAlvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility
Carfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexTozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigationalComirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350] … [L15027] On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) based on 95% efficacy in clinical trials and a similar safety profile to other viral vaccines over a span of approximately
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigationalZolbetuximab (previously claudiximab)[A264748] is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Grazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis].
Benzylpenicilloyl polylysine
go.drugbank.com/drugs/DB00895ApprovedInvestigationalBenzylpenicilloyl polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. … The quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects.
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. … [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845]
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalL10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. … [A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigationalTislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.
Categories: Programmed Death Receptor-1 Blocking Antibody